



Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments

Information for the public Published: 31 January 2024

www.nice.org.uk

Loncastuximab tesirine (Zynlonta) is available on the NHS. It is a possible treatment for diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults whose cancer has returned (relapsed) or stopped responding (refractory) after 2 or more systemic treatments. Systemic treatments are medicines that work throughout the whole body. They can include injections, infusions or medicines taken by mouth.

To have loncastuximab tesirine you must have previously had, or cannot have, polatuzumab vedotin.

Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments

If you are not eligible for loncastuximab tesirine but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS webpage on non-Hodgkin lymphoma may be a good place to find out more.

These organisations can give you advice and support:

- Lymphoma Action, 0808 808 5555
- Blood Cancer UK, 0808 2080 888
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5666-1